Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
Public ClinicalTrials.gov record NCT03552276. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
Study identification
- NCT ID
- NCT03552276
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 281 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 11, 2018 (Actual)
- Primary completion
- Sep 18, 2023 (Actual)
- Completion
- Sep 18, 2023 (Actual)
- Last update posted
- Nov 21, 2024
2018 – 2023
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 25 | Glendale | Arizona | 85306 | — |
| Site 16 | Phoenix | Arizona | 85032 | — |
| Site 14 | Denver | Colorado | 80230 | — |
| Site 27 | Wichita | Kansas | 67207 | — |
| Site 23 | Lexington | Kentucky | 40504 | — |
| Site 20 | Monroe | Louisiana | 71203 | — |
| Site 26 | Lebanon | New Hampshire | 03756 | — |
| Site 24 | Salisbury | North Carolina | 28144 | — |
| Site 19 | Cincinnati | Ohio | 45242 | — |
| Site 17 | Middleburg Heights | Ohio | 44130 | — |
| Site 18 | Memphis | Tennessee | 38119 | — |
| Site 21 | Seattle | Washington | 98122 | — |
| Site 22 | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03552276, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2024 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03552276 live on ClinicalTrials.gov.